Cargando…

Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR(L858R/T790M) mutation

Purpose: Drug resistance is a major challenge for epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) treatment of lung cancer. Ferumoxytol (FMT) drives macrophage (MΦ) transformation towards a M1-like phenotype and thereby inhibits tumor growth. CpG oligodeoxynucleotide 2395 (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Guoqun, Zhao, Jiaojiao, Zhang, Meiling, Wang, Qian, Chen, Bo, Hou, Yayi, Lu, Kaihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599896/ https://www.ncbi.nlm.nih.gov/pubmed/31417255 http://dx.doi.org/10.2147/IJN.S193583

Ejemplares similares

CpG oligodeoxynucleotides as mucosal adjuvants
por: Iho, Sumiko, et al.
Publicado: (2015)

CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody
por: Hiramatsu, Kosuke, et al.
Publicado: (2015)

Type II natural killer T cells foster the antitumor activity of CpG-oligodeoxynucleotides
por: Zhao, Jie, et al.
Publicado: (2014)

Design and Synthesis of New Hydantoin Acetanilide Derivatives as Anti-NSCLC Targeting EGFR(L858R/T790M) Mutations
por: Hassanin, Moamen A., et al.
Publicado: (2022)

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells
por: Wu, Hong, et al.
Publicado: (2015)

Systemic Administration of CpG Oligodeoxynucleotide and Levamisole as Adjuvants for Gene-Gun-Delivered Antitumor DNA Vaccines
por: Šmahel, Michal, et al.
Publicado: (2011)

Neonate Intestinal Immune Response to CpG Oligodeoxynucleotide Stimulation
por: Lacroix-Lamandé, Sonia, et al.
Publicado: (2009)

Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer
por: Sun, Peiyuan, et al.
Publicado: (2021)

Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports
por: Li, Guangrui, et al.
Publicado: (2023)

CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts
por: De Cesare, Michelandrea, et al.
Publicado: (2016)

Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system
por: Hanagata, Nobutaka
Publicado: (2012)

A Novel C Type CpG Oligodeoxynucleotide Exhibits Immunostimulatory Activity In Vitro and Enhances Antitumor Effect In Vivo
por: Li, Tete, et al.
Publicado: (2020)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023)

Simultaneous Detection of the T790M and L858R Mutations in the EGFR Gene by Oligoribonucleotide Interference-PCR
por: Baba, Keisuke, et al.
Publicado: (2019)

Anti-tumor macrophages activated by ferumoxytol combined or surface-functionalized with the TLR3 agonist poly (I : C) promote melanoma regression
por: zhao, Jiaojiao, et al.
Publicado: (2018)

Cooperative Stimulation of Dendritic Cells by Cryptococcus neoformans Mannoproteins and CpG Oligodeoxynucleotides
por: Dan, Jennifer M., et al.
Publicado: (2008)

CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies
por: Hanagata, Nobutaka
Publicado: (2017)

Synergistic oligodeoxynucleotide strongly promotes CpG-induced interleukin-6 production
por: Nigar, Shireen, et al.
Publicado: (2017)

A CpG oligodeoxynucleotide enhances the immune response to rabies vaccination in mice
por: Yu, Pengcheng, et al.
Publicado: (2018)

Lipid Nanoparticles Potentiate CpG-Oligodeoxynucleotide-Based Vaccine for Influenza Virus
por: Shirai, Seiki, et al.
Publicado: (2020)

CpG Oligodeoxynucleotides for Anticancer Monotherapy from Preclinical Stages to Clinical Trials
por: Zhang, Zhongkun, et al.
Publicado: (2021)

Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity
por: Cerkovnik, Petra, et al.
Publicado: (2010)

Differential MicroRNA Expression between EGFR T790M and L858R Mutated Lung Cancer
por: Kim, Ji Yeon, et al.
Publicado: (2018)

A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma
por: Fawwaz, Muammar, et al.
Publicado: (2021)

Antitumor efficacy of multi-target in situ vaccinations with CpG oligodeoxynucleotides, anti-OX40, anti-PD1 antibodies, and aptamers
por: Proskurina, Anastasia S., et al.
Publicado: (2023)

CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity
por: Chu, Rose S., et al.
Publicado: (1997)

CpG-Oligodeoxynucleotide Treatment Protects against Ionizing Radiation-Induced Intestine Injury
por: Zhang, Chao, et al.
Publicado: (2013)

Effects of CpG oligodeoxynucleotide 1826 on acute radiation-induced lung injury in mice
por: Li, Xuan, et al.
Publicado: (2016)

Immunostimulatory Activities of CpG-Oligodeoxynucleotides in Teleosts: Toll-Like Receptors 9 and 21
por: Lai, Chao-Yang, et al.
Publicado: (2019)

Role of Kupffer cells in liver injury induced by CpG oligodeoxynucleotide and flucloxacillin in mice
por: Gao, Yuying, et al.
Publicado: (2020)

Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide
por: Bao, Musheng, et al.
Publicado: (2006)

CpG oligodeoxynucleotides inhibit the proliferation and osteoclastic differentiation of RAW264.7 cells
por: Zheng, Yi, et al.
Publicado: (2020)

Unusual metachronous lung adenocarcinomas harboring EGFR L858R/T790M mutations: A case report
por: Pei, Guotian, et al.
Publicado: (2020)

Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts
por: Hu, Peng, et al.
Publicado: (2016)

Gossypol Inhibits Non-small Cell Lung Cancer Cells Proliferation by Targeting EGFR(L858R/T790M)
por: Wang, Yuwei, et al.
Publicado: (2018)

Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR
por: Foschi, Francesca, et al.
Publicado: (2022)

Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers
por: Cooper, Curtis L, et al.
Publicado: (2008)

CpG oligodeoxynucleotide stimulates production of anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitis
por: Hurtado, Plinio R, et al.
Publicado: (2008)

Intratracheal synthetic CpG oligodeoxynucleotide causes acute lung injury with systemic inflammatory response
por: Tasaka, Sadatomo, et al.
Publicado: (2009)

Development of CpG-Oligodeoxynucleotides for Effective Activation of Rabbit TLR9 Mediated Immune Responses
por: Chuang, Tsung-Hsien, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ddmnd6q54p5velp0o4d702oomv